Table 3.

CVD mortality by treatment regimen for a population-based sample of breast cancer survivors and women without breast cancer. Long Island Breast Cancer Study Project, 1996-2009.

	Cause-specific HRa,b (95% CI)
Treatment	Women without Breast Cancer	Breast Cancer Survivors without Treatment	Breast Cancer Survivors with Treatment
Chemotherapy	1.0	1.1 (0.82, 1.6)	1.7 (1.1, 2.6)
Hormone Therapy	1.0	1.3 (0.82, 1.9)	1.3 (0.93, 1.8)
Radiation Therapy	1.0	1.5 (1.0, 2.2)	1.2 (0.82, 1.7)
	Subdistribution HRa,c (95% CI)
Treatment	Women without Breast Cancer	Breast Cancer Survivors without Treatment	Breast Cancer Survivors with Treatment
Chemotherapy	1.0	1.1 (0.77, 1.5)	1.4 (0.95, 2.2)
Hormone Therapy	1.0	1.2 (0.77, 1.8)	1.2 (0.86, 1.7)
Radiation Therapy	1.0	1.3 (0.89, 2.0)	1.1 (0.77, 1.6)

^aModels adjusted for age at reference date (date of diagnosis for breast cancer survivors and date of identification for women without breast cancer), menopausal status, previous use of hormone replacement therapy, smoking history, average lifetime alcohol intake, body mass index the year before reference date, income, education, and history of the following cardiovascular disease risk factors: diabetes, myocardial infarction, hypertension, dyslipidemia or stroke. Models also included interaction between follow-up time and history of diabetes.

^bCause-specific hazard ratio estimates relative rate of CVD mortality between women with and without breast cancer, not accounting for competing causes of death.

^cSubdistribution hazard ratio reflects association between breast cancer diagnosis and incidence of CVD death.